Platelet-rich plasma growth factor receptors

Platelet-rich plasma (PRP) therapy functions by delivering a concentrated dose of autologous platelets to a site of injury, where they release a variety of growth factors from their alpha-granules. These ligands, including Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-β), and Vascular Endothelial Growth Factor (VEGF), act on their respective endogenous receptors—such as PDGFR, TGFβR, and VEGFR—to stimulate tissue repair (StatPearls, 2023). The activation of these receptors triggers downstream signaling cascades, including the MAPK and PI3K/Akt pathways, which are essential for cell proliferation, migration, and the synthesis of extracellular matrix components (NCBI, PMC6220008). Clinically, PRP is employed to treat a range of conditions, most notably osteoarthritis, chronic tendinopathies, and androgenetic alopecia, by leveraging the body's natural healing mechanisms (PubMed, 30244387). While generally safe due to its autologous nature, the therapeutic outcomes of PRP can be inconsistent due to differences in platelet concentration and preparation techniques across different clinical settings (PubMed, 31145533).

Other names

PRP receptorsPlatelet-derived growth factor receptorsTransforming growth factor-beta receptorsVascular endothelial growth factor receptorsEpidermal growth factor receptorsInsulin-like growth factor 1 receptorsFibroblast growth factor receptors

Agonism of multiple endogenous growth factor receptors (PDGFR, TGFBR, VEGFR, EGFR, IGFR, FGFR) by ligands released from activated platelets